Interleukin-33 in asthma: how big of a role does it play?

Interleukin-33 in asthma: how big of a role does it play?

In complex disorders such as asthma and allergic disease, the goal for developing disease-modifying biother-apeutics is to find a target that is a central instigator of immunologic activity. Interleukin (IL)-33 seems to be such a molecule, as it is one of the earliest-released signaling molecules following epithelial damage and can orchestrate the recruitment and activation of the cells responsible for disease. Unregulated IL-33 activity leads to activation of T-helper type 2 cells, mast cells, dendritic cells, eosinophils, and basophils, ultimately leading to increased expression of cytokines and chemokines that define the disease. As such, IL-33 is an attractive candidate for therapeutic intervention with the goal of ameliorating disease. This review focuses on the role of IL-33 in promoting and maintaining the asthma phenotype.

在哮喘和过敏性疾病等复杂疾病中，开发疾病修饰生物疗法的目标是找到一个作为免疫活动核心引发因素的靶点。白细胞介素（IL）-33似乎就是这样一种分子，因为它是上皮损伤后最早释放的信号分子之一，并且能够协调负责疾病的细胞的募集和激活。IL - 33活性失调会导致2型辅助性T细胞、肥大细胞、树突状细胞、嗜酸性粒细胞和嗜碱性粒细胞活化，最终导致定义该疾病的细胞因子和趋化因子表达增加。因此，IL - 33是一个有吸引力的治疗干预候选靶点，目的是改善疾病。这篇综述重点关注IL - 33在促进和维持哮喘表型中的作用。